Advertisement
Document › Details
Wacker Chemie AG. (12/8/21). "Press Release: Aleph Farms and Wacker Develop Open Supply Chain Solution for Proteins Used in Large-Scale Production of Cultivated Meat". Munich & Rehovot.
Organisation | Wacker Biosolutions division | |
Today | Chemovator GmbH | |
Group | Wacker (Group) | |
Organisation 2 | Aleph Farms (IL) | |
Product | cell culture media | |
Product 2 | meat, cultured / clean | |
Index term | Aleph Farms–Wacker: cell culture media, 202112– collab developm production process for growth-medium proteins for cultured meat | |
Person | Toubia, Didier (Aleph Farms 202112 CEO + Co-Founder) | |
Person 2 | Leonhartsberger, Susanne (Wacker 202007 Head of Biosolutions Division) | |
> WACKER’S PRODUCTION TECHNOLOGIES, SUPPORTED AND VALIDATED BY ALEPH FARMS, WILL PROVIDE FOOD-GRADE GROWTH-MEDIUM PROTEINS TO THE ENTIRE INDUSTRY
> THE AIM IS TO ELIMINATE SIGNIFICANT COST BARRIERS FOR WIDE-SCALE CULTIVATED MEAT PRODUCTION.
Joint press release by WACKER and Aleph Farms
Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells and WACKER, a supplier of leading protein production technologies, today announced the development of streamlined production processes for essential growth medium proteins to cost-effectively grow cultivated meat. These proteins, central to promoting and supporting cell growth, are not widely available in the market today and represent one of the most prohibitive expenses in scaling up cultivated meat. The agreement between WACKER and Aleph Farms is non-exclusive, meaning any cultivated meat company will be able to obtain these same affordable proteins, without using fetal bovine serum (FBS) or animal-derived ingredients. This open supply chain solution is expected to enable the industry to scale and achieve price-parity faster, eliminating a key hurdle in the commercial viability of cultivated meat.
"Bringing down the cost and making suitable raw materials available at this key moment in the scale-up of production is imperative to taking cultivated meat mainstream and driving impact”, said Didier Toubia, Co-Founder and CEO of Aleph Farms. "Investing in the development of a supply chain solution available to the entire industry is a direct result of our innovative and inclusive business model and the impetus behind our partnership with WACKER. Our team’s scientific expertise alongside WACKER’s vast experience, makes it possible to produce proteins at the quantity, quality and cost necessary to meet Aleph’s aggressive goal of achieving cost-parity with conventional meat."
WACKER brings over 20 years of experience in protein production to the partnership, as well as a deep understanding of the food industry’s requirements and regulations. At its corporate research labs in Munich, WACKER is working on fermentation techniques for producing cell culture proteins for use in food applications, which will have the same composition of proteins produced inside the animal’s body. Similar production techniques are widely used today to produce enzymes for food processing applications.
“The market for cultivated meat is advancing rapidly and we want to contribute to making it an affordable reality for everyone,” said Susanne Leonhartsberger, president of WACKER BIOSOLUTIONS, WACKER´s life science division. “At WACKER, we have many years of experience in the field of protein production. Our scientists have developed advanced production technologies that we can draw on. With this platform, we are now entering the field of cultivated meat. As the most technologically advanced company in the field, Aleph Farms is an ideal partner for us in this project.”
Growth-medium proteins are essential components naturally found in animals and today represent the main cost drivers of cultivated meat production. They act as a nutrient-rich feed to help cells grow and mature into muscle, fat and collagen-producing cells and are imperative for supporting cellular activity. The aim is for this partnership to realize a significant reduction in the cost of these proteins by matching the standard of quality and scale to the food industry. The proteins are to be made available to all cultivated meat companies in the industry.
About WACKER BIOSOLUTIONS
Using advanced biotech processes, WACKER BIOSOLUTIONS provides tailored, innovative solutions and products to the life-sciences sector – including pharmaceutical proteins, cyclodextrins and fermentation-generated cysteine. The portfolio is additionally complemented with catalog chemicals such as acetylacetone. The division focuses on developing customized solutions for growth sectors, such as food ingredients, pharmaceutical activities and agrochemicals. WACKER BIOSOLUTIONS is the life science division of the Munich based WACKER group.
For more information visit www.wacker.com
About Aleph Farms
Aleph Farms grows beef steaks, from non-genetically engineered and non-immortalized cells isolated from a living cow, without slaughtering the animal and with a significantly reduced impact to the environment. The company was co-founded in 2017 by Didier Toubia, The Kitchen Hub of the Strauss Group, and Professor Shulamit Levenberg from the Biomedical Engineering Faculty at the Technion - Israel Institute of Technology. The company’s vision is to provide unconditional quality nutrition for anyone, anytime, anywhere.
For more information, follow Aleph Farms on
Instagram,
Twitter,
Facebook or
LinkedIn or visit
www.aleph-farms.com.
Contact
Media Contact
Wacker Chemie AG
Media Relations & Information
Manuela Dollinger
Tel. +49 89 6279-1629
Send message
Aleph Farms
Songue PR für Aleph Farms
Natalee Gibson
Tel.: +1 720 648 5784
alephfarms@songuepr.com
Record changed: 2023-06-05 |
Advertisement
More documents for Wacker (Group)
- [1] Wacker Chemie AG. (5/6/24). "Press Release: Wacker Expands Production Capacity for Biopharmaceuticals in San Diego". Munich & San Diego, CA....
- [2] Pantherna Therapeutics GmbH / Wacker. (4/5/24). "Press Release: Pantherna and Wacker Intensify Collaboration in the Development and Production of mRNA Biopharmaceuticals". Munich & Hennigsdorf....
- [3] Wacker Chemie AG. (5/8/23). "Press Release: Wacker Purchases ADL BioPharma in Spain, Strengthening Its Biotechnology Business". Munich & León....
- [4] Wacker Chemie AG. (10/12/22). "Press Release: Neuway Pharma and Wacker Launch Research Project to Develop RNA-Based Actives for the Treatment of Central Nervous System Diseases". Munich & Bonn....
- [5] Wacker Chemie AG. (7/5/22). "Press Release: Wacker to Start Construction of Competence Center for mRNA Actives at Halle Site". Tübingen & Boston, MA....
- [6] Wacker Chemie AG. (6/2/22). "Press Release: Wacker to Invest Double-Digit Million-Euro Sum in Biotechnology Center". Munich....
- [7] mk2 Biotechnologies GmbH. (6/7/22). "Press Release: mk2 Biotechnologies, Wacker and TUM Jointly Develop a Process for the Large-scale Production of Antimicrobial Peptides Based on Sustainable Fermentation"....
- [8] Wacker Chemie AG. (1/17/22). "Press Release: Plasmitec – Wacker Introduces Its Plasmid DNA Production Platform". Munich & San Diego, CA....
- [9] Wacker Chemie AG. (1/11/22). "Press Release: Wacker and Biosyntia Develop Large-Scale Production Process for Sustainable Biotin". Munich & Copenhagen....
- [10] Wacker Chemie AG. (12/14/21). "Press Release: Wacker and CordenPharma Develop Solutions for Formulating Lipid Nanoparticles Expanding Their Portfolio for Advanced Medicines". Munich & Luxembourg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top